Published in Vaccine Weekly, February 9th, 2000
Under the CRADA, Avant will provide its proprietary Therapore technology to generate specific immune responses against the HIV genomic sequence. Experts believe that an immune response created by a vaccine against the gene carried inside HIV has the potential to prevent infection by the virus and subsequently to protect individuals from developing acquired...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.